COGT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COGT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cogent Biosciences's retained earnings for the quarter that ended in Mar. 2024 was $-661.97 Mil.
Cogent Biosciences's quarterly retained earnings declined from Sep. 2023 ($-549.26 Mil) to Dec. 2023 ($-603.62 Mil) and declined from Dec. 2023 ($-603.62 Mil) to Mar. 2024 ($-661.97 Mil).
Cogent Biosciences's annual retained earnings declined from Dec. 2021 ($-270.97 Mil) to Dec. 2022 ($-411.21 Mil) and declined from Dec. 2022 ($-411.21 Mil) to Dec. 2023 ($-603.62 Mil).
The historical data trend for Cogent Biosciences's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Retained Earnings | Get a 7-Day Free Trial | -123.89 | -198.70 | -270.97 | -411.21 | -603.62 |
Cogent Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Retained Earnings | Get a 7-Day Free Trial | -449.80 | -493.88 | -549.26 | -603.62 | -661.97 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Cogent Biosciences (NAS:COGT) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Fairmount Funds Management Llc | 10 percent owner, other: See Remarks | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Evan Kearns | officer: Chief Legal Officer | AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421 |
John L. Green | officer: Chief Financial Officer | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
John Edward Robinson | officer: Chief Scientific Officer | C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140 |
Christopher W. Cain | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Peter Evan Harwin | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Arlene Morris | director | C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304 |
Todd Shegog | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Jessica Sachs | officer: Chief Medical Officer | C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Matthew Ros | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Karen Jean Ferrante | director | 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818 |
Andrew R Robbins | director, officer: President and CEO | C/O 3200 WALNUT ST, BOULDER CO 80301 |
Venrock Healthcare Capital Partners Iii, L.p. | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Vhcp Management Iii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
Vhcp Management Ii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
From GuruFocus
By sperokesalga sperokesalga • 05-09-2023
By GlobeNewswire GlobeNewswire • 06-03-2023
By sperokesalga sperokesalga • 06-03-2023
By GlobeNewswire GlobeNewswire • 12-11-2022
By Value_Insider Value_Insider • 12-11-2022
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 11-02-2023
By GlobeNewswire • 10-14-2023
By Value_Insider Value_Insider • 11-03-2022
By sperokesalga sperokesalga • 06-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.